RESUMO
Hepatocellular carcinoma is the fifth most common type of cancer worldwide and remains difficult to treat. The aim of this study was to investigate the effects of mesenchymal stem cells (MSCs) derived from the umbilical cord (UCMSCs) on HepG2 hepatocellular carcinoma cells. UCMSCs were cocultured with HepG2 cells and biomarkers of UCMSCs were analyzed by flow cytometry. mRNA and protein expression of genes were determined by reverse transcriptionpolymerase chain reaction and flow cytometry, respectively. Passage three and seven UCMSCs expressed CD29, CD44, CD90 and CD105, whereas CD34 and CD45 were absent on these cells. Coculture with UCMSCs inhibited proliferation and promoted apoptosis of HepG2 cells in a timedependent manner. The initial seeding density of UCMSCs also influenced the proliferation and apoptosis of HepG2 cells, with an increased number of UCMSCs causing enhanced proliferation inhibition and cell apoptosis. Coculture with UCMSCs downregulated mRNA and protein expression of αfetoprotein (AFP), Bcl2 and Survivin in HepG2 cells. Thus, UCMSCs may inhibit growth and promote apoptosis of HepG2 cells through downregulation of AFP, Bcl2 and Survivin. US-MSCs may be used as a novel therapy for treating hepatocellular carcinoma in the future.
Assuntos
Apoptose , Células-Tronco Mesenquimais/citologia , Células-Tronco Mesenquimais/metabolismo , Cordão Umbilical/citologia , Antígenos de Superfície/metabolismo , Biomarcadores , Biomarcadores Tumorais , Diferenciação Celular , Proliferação de Células , Técnicas de Cocultura , Regulação Neoplásica da Expressão Gênica , Células Hep G2 , Humanos , Imunofenotipagem , RNA Mensageiro/genética , RNA Mensageiro/metabolismoRESUMO
In order to provide non-invasive, reliable and sensitive laboratory parameters for the diagnosis of primary biliary cirrhosis (PBC), metabolic technology of ultraperformance liquid chromatography coupled with quadrupole-time-of-flight mass spectrometry (UPLC/Q-TOF MS) was used to compare small molecule metabolites in blood and urine from patients with PBC and healthy controls. We then screened for bio-markers in the blood and urine of the patients with PBC. Data were processed by Bruker ProfileAnalysis metabonomic software and imported to SIMCA-P software, which utilized principal component analysis (PCA) to create models of patients with PBC and healthy controls. In total, 18 urinary markers were found and the levels of 11 of these urinary markers were elevated in the patients with PBC, whereas the levels of the remaining 7 markers were lower in the PBC group compared to the control group. We also identified 20 blood-based biomarkers in the patients with PBC and the levels of 9 of these markers were higher in the PBC group, whereas the levels of the remaining 11 markers were lower in the patients with PBC compared to the controls. Among these biomarkers, the levels of bile acids increased with the progression of PBC, while the levels of carnitines, such as propionyl carnitine and butyryl carnitine, decreased with the progression of PBC. In conclusion, the findings of the present study suggest that the circulating levels of bile acids and carnitine are differentially altered in patients with PBC.